FOXP3 and asthma: It is possible that the deeper knowledge of immune biomarkers, such as FOXP3, its changes in expressions, and modifications, as well as the changes of the expression of other parameters related to asthma, will enable new targeted therapies in the future and provide, in addition to anti-inflammatory drugs, new pillars of asthma therapy.